PMID- 24312008
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20140310
LR  - 20211021
IS  - 1662-5102 (Print)
IS  - 1662-5102 (Electronic)
IS  - 1662-5102 (Linking)
VI  - 7
DP  - 2013 Nov 20
TI  - Neuroplasticity and the next wave of antidepressant strategies.
PG  - 218
LID - 10.3389/fncel.2013.00218 [doi]
LID - 218
AB  - Depression is a common chronic psychiatric disorder that is also often co-morbid 
      with numerous neurological and immune diseases. Accumulating evidence indicates 
      that disturbances of neuroplasticity occur with depression, including reductions 
      of hippocampal neurogenesis and cortical synaptogenesis. Improper trophic support 
      stemming from stressor-induced reductions of growth factors, most notably brain 
      derived neurotrophic factor (BDNF), likely drives such aberrant neuroplasticity. 
      We posit that psychological and immune stressors can interact upon a vulnerable 
      genetic background to promote depression by disturbing BDNF and neuroplastic 
      processes. Furthermore, the chronic and commonly relapsing nature of depression 
      is suggested to stem from "faulty wiring" of emotional circuits driven by 
      neuroplastic aberrations. The present review considers depression in such terms 
      and attempts to integrate the available evidence indicating that the efficacy of 
      current and "next wave" antidepressant treatments, whether used alone or in 
      combination, is at least partially tied to their ability to modulate 
      neuroplasticity. We particularly focus on the N-methyl-D-aspartate (NMDA) 
      antagonist, ketamine, which already has well documented rapid antidepressant 
      effects, and the trophic cytokine, erythropoietin (EPO), which we propose as a 
      potential adjunctive antidepressant agent.
FAU - Hayley, Shawn
AU  - Hayley S
AD  - Department of Neuroscience, Carleton University Ottawa, ON, Canada.
FAU - Litteljohn, Darcy
AU  - Litteljohn D
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20131120
PL  - Switzerland
TA  - Front Cell Neurosci
JT  - Frontiers in cellular neuroscience
JID - 101477935
PMC - PMC3834236
OTO - NOTNLM
OT  - BDNF
OT  - combined treatment
OT  - depression
OT  - erythropoietin
OT  - ketamine
OT  - neurogenesis
OT  - relapse
EDAT- 2013/12/07 06:00
MHDA- 2013/12/07 06:01
PMCR- 2013/01/01
CRDT- 2013/12/07 06:00
PHST- 2013/04/17 00:00 [received]
PHST- 2013/10/29 00:00 [accepted]
PHST- 2013/12/07 06:00 [entrez]
PHST- 2013/12/07 06:00 [pubmed]
PHST- 2013/12/07 06:01 [medline]
PHST- 2013/01/01 00:00 [pmc-release]
AID - 10.3389/fncel.2013.00218 [doi]
PST - epublish
SO  - Front Cell Neurosci. 2013 Nov 20;7:218. doi: 10.3389/fncel.2013.00218.